Abstract:Background: The development of intrinsic and acquired resistance to antineoplastic agents is a major obstacle to successful chemotherapy in ovarian cancers. Identification and characterisation of chemoresponse-associated biomarkers are of paramount importance for novel therapeutic development. Methods: Global RNA expression profiles were obtained by high-throughput microarray analysis. Cell cycle, proliferation rate, and paclitaxel sensitivity of ovarian cancer cells harbouring cyclin A1-inducible expression construct were compared with and without tetracycline induction, as well as when the cyclin A1 expression was suppressed by short inhibiting RNA (siRNA). Cellular senescence was evaluated by β-galactosidase activity staining. Results: Global RNA expression profiling and subsequent correlation studies of gene expression level and drug response has identified that elevated expression of cyclin A1 (CCNA1) was significantly associated with cellular resistance to paclitaxel, doxorubicin and 5-fluorouracil. The role of cyclin A1 in paclitaxel resistance was confirmed in ovarian cancer cells that harbour an inducible cyclin A1 expression construct, which showed reduced paclitaxel-mediated growth inhibition and apoptosis when cyclin A1 expression was induced, whereas downregulation of cyclin A1 expression in the same cell lines using cyclin A1-specific siRNAs sensitised the cells to paclitaxel toxicity. However, ovarian cancer cells with ectopic expression of cyclin A1 demonstrated slowdown of proliferation and senescence-associated β-galactosidase activity. Conclusions: Our profiling and correlation studies have identified cyclin A1 as one chemoresistance-associated biomarker in ovarian cancer. The results of the characterisation studies suggest that cyclin A1 functions as an oncogene that controls proliferative and survival activities in tumourigenesis and chemoresistance of ovarian cancer.

Oligo-microarray analysis reveals the role of cyclophilin A in drug resistance

Cyclo-Oxygenase 2 Up-Regulates the Effect of Multidrug Resistance

Integrated Genomic and Proteomic Analyses Identify PYGL As a Novel Experimental Therapeutic Target for Clear Cell Renal Cell Carcinoma

Cyclophilin J Is a Novel Peptidyl-Prolyl Isomerase and Target for Repressing the Growth of Hepatocellular Carcinoma

Cyclophilin A Promotes Human Hepatocellular Carcinoma Cell Metastasis Via Regulation of Mmp3 and Mmp9

Cypa, A Gene Downstream Of Hif-1 Alpha, Promotes The Development Of Pdac

Cyclophilin A is upregulated in small cell lung cancer and activates ERK1/2 signal.

The Progress of Cyclophilin A in Cancer Research

Cyclophilin A: promising target in cancer therapy

Overexpression of SMARCA2 or CAMK2D is Associated with Cisplatin Resistance in Human Epithelial Ovarian Cancer

Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways

Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer

Cyclophilin A Inhibits A549 Cell Oxidative Stress And Apoptosis By Modulating The Pi3k/Akt/Mtor Signaling Pathway

A novel role for the peptidyl-prolyl cis-trans isomerase Cyclophilin A in DNA-repair following replication fork stalling via the MRE11-RAD50-NBS1 complex

Downregulation of CyclophilinA/CD147 Axis Induces Cell Apoptosis and Inhibits Glioma Aggressiveness.

Cyclophilin D: Guardian or Executioner for Tumor Cells?

Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells

Down-regulation of focal adhesion signaling in response to cyclophilin A knockdown in human endometrial cancer cells, implicated by cDNA microarray analysis

Elucidating the role of CYFIP2 in conferring cisplatin resistance in esophageal squamous cell carcinoma

PGC1 Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway

Identification Of Cyclophilin A As A Potential Prognostic Factor For Clear-Cell Renal Cell Carcinoma By Comparative Proteomic Analysis